Carolyn Porter

Company: Outrun Therapeutics

Job title: CEO

Seminars:

A Novel Approach to Targeted Protein Stabilization via E3 Ligase Inhibition 12:00 pm

E3 ligase inhibition to stabilize proteins otherwise degraded in disease is an untapped therapeutic modality Introducing a novel platform for identification of direct inhibitors of E3 ligases and novel E3 ligases Selective and potent small molecule inhibitors of E3 ligases have been identified that stabilize tumour suppressor proteins and induce cell death in target tumour…Read more

day: Post-Conference Focus Day